Clinical trials: CRS
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.
- Trial name
- NCT05248997
- Testing
- rimegepant 75 mg ODT
- Where
- 33 sites in United States
- Volunteers
- 261 people
- Sponsor
- Pfizer
Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally…
- Conditions
- Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
- Trial name
- SURF201 (NCT06160752)
- Testing
- Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Tyra Biosciences, Inc
URTI, Bronchiolitis
Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms
The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.
- Conditions
- URTI, Bronchiolitis, COVID - 19, Allergic Rhinitis
- Trial name
- SeaBridge (NCT07262450)
- Testing
- Respimer® Hygiene-Prevention -Baby, kids, adults, Respimer® Hygiene-Prevention Kids, adults, Respimer® Decongestion Baby, kids, adults
- Where
- 32 sites in France
- Volunteers
- 1,065 people
- Sponsor
- Laboratoire de la Mer
UC (Urothelial Cancer)
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
- Trial name
- NCT02872714
- Testing
- pemigatinib
- Where
- 96 sites in United States, Belgium and 9 more
- Volunteers
- 263 people
- Sponsor
- Incyte Corporation
Rhinosinusitis
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
The study should create data for the selection of a clinically relevant endpoint to assess the potential of Buparid/PARI SINUS to postpone sinus surgery in patients with chronic Rhinosinusitis.
- Trial name
- NCT01955980
- Testing
- Budesonide
- Where
- 3 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Pari Pharma GmbH
Non-Small Cell Lung Cancer (NSCLC)
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who…
- Trial name
- FIGHT-210 (NCT05253807)
- Testing
- Pemigatinib
- Where
- 36 sites in United States, France and 3 more
- Volunteers
- 8 people
- Sponsor
- Incyte Corporation
Rhinosinusitis, Chronic Polyposis
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis (CRS) with…
- Trial name
- NCT01946711
- Testing
- Budesonide
- Where
- 4 sites in Germany
- Volunteers
- 14 people
- Sponsor
- Pari Pharma GmbH
Chronic Rhinosinusitis (CRS)
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray
The goal of this clinical study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VVN432 Nasal Spray in healthy volunteers (Phase Ia) and in patients with chronic rhinosinusitis (Phase 1b).
- Trial name
- NCT07259538
- Testing
- 0.5% VVN432 Nasal Spray, 1% VVN432 Nasal Spray, Vehicle
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VivaVision Biotech, Inc
Chronic Rhinosinusitis
Canadian Health Economics, Outcome, and Effectiveness Comparison of Treatment in Patients With Chronic Rhinosinusitis
The economic, patient related outcome, and effectiveness of balloon sinuplasty in the treatment of CRS patients with frontal and other sinus disease in the Canadian healthcare environment is not known at this time.
- Trial name
- CHEC (NCT01455948)
- Testing
- Relieva Balloon Sinuplasty™ System, Functional Endoscopic Sinus Surgery
- Where
- 8 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Integra LifeSciences Corporation
Neoplasm
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
The primary purpose of this study is to evaluate objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of erdafitinib in a molecularly-defined subset of Asian participants with…
- Trial name
- NCT02699606
- Testing
- Erdafitinib
- Where
- 6 sites in China, South Korea and 1 more
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer
- Trial name
- NCT03144661
- Testing
- INCB062079
- Where
- 6 sites in United States, Belgium
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Cholangiocarcinoma
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
The primary purpose of the study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable…
- Trial name
- NCT04238715
- Testing
- E7090
- Where
- 56 sites in China, Japan
- Volunteers
- 63 people
- Sponsor
- Eisai Co., Ltd.
Peritoneal Carcinomatosis, Ovarian Cancer
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
RAD-18-001 is a First-In-Man, Dose Escalation study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq.
- Trial name
- NCT03732768
- Testing
- Radspherin
- Where
- 4 sites in Belgium, Norway and 1 more
- Volunteers
- 21 people
- Sponsor
- Oncoinvent Solutions AS
Relapsed/Refractory Multiple Myeloma (RRMM)
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who…
- Trial name
- POPLIN (NCT07609940)
- Testing
- Linvoseltamab, Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis
This is a prospective, multicenter, randomized, controlled, double-blind clinical trial enrolling 300 adult subjects with chronic rhinosinusitis (CRS) with and without nasal polyps (CRSwNP and CRSsNP) indicated for endoscopic…
- Trial name
- RESTORE-2 RCT (NCT07290140)
- Testing
- Airiver ESSpand DCB, ESS
- Where
- 16 sites in United States
- Volunteers
- 300 people
- Sponsor
- Airiver Medical, Inc.
Chronic Rhinosinusitis (CRS)
Product Surveillance Registry; Ear, Nose and Throat - EXTEND Cohort
The purpose of this study is to confirm long-term clinical safety and performance, acceptability of identified risks, and detect emerging risks based on factual evidence for the PROPEL family of products when used according to…
- Trial name
- NCT06671561
- Testing
- Observational data collection from patients with chronic rhinosinusitis (CRS) receiving PROPEL sinus implant(s) following functional endoscopic sinus surgery (FESS)
- Sponsor
- Medtronic
Breast Neoplasms
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to…
- Trial name
- NCT04572295
- Testing
- E7090, Fulvestrant, Exemestane
- Where
- 11 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Eisai Co., Ltd.
Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.
- Trial name
- NCT01928459
- Testing
- BGJ398, BYL719
- Where
- 22 sites in United States, Australia and 10 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
- Trial name
- ECLIPSE (NCT02004262)
- Testing
- GVAX Pancreas Vaccine, CRS-207, Chemotherapy
- Where
- 21 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- Aduro Biotech, Inc.
Urothelial Cancer, Receptors, Fibroblast Growth Factor
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.
- Trial name
- NCT03955913
- Testing
- Archival Tumor Tissue Sample
- Where
- 199 sites in United States, Argentina and 12 more
- Volunteers
- 3,679 people
- Sponsor
- Janssen Research & Development, LLC